Skip to content

Released Aug 6, 2025, after the close

10-Q filed Aug 6, 2025, 37 days after period end · 0000950170-25-104060

Q2 2025 · 10-Q
Revenue$9.63M+12.8% vs Q2 2024+2.2% vs Q1 2025
Net Income-$10.20MN/M vs Q2 2024N/M vs Q1 2025
EPS Diluted-$1.33N/M vs Q2 2024N/M vs Q1 2025
Operating Income-$11,093,000N/M
Operating Cash Flowderived-$16,758,000N/M
Free Cash Flowderived-$16,758,000N/M
Margins · derived
Operating margin-115.2%+27.8 pt vs Q2 2024
Net margin-105.9%+24.8 pt vs Q2 2024

What the release said

The release

Same quarter

MetricQ2 2025Q2 2024Q2 2023Q2 2022
Revenue$9.63M$8.53M$0.00—
Net Income-$10.20M-$11.15M-$16.90M-$24.46M
EPS Diluted-$1.33-$1.98-$3.88-$0.51

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Assembly Biosciences, Inc. · CIK 1426800 · Engraved from SEC EDGAR